Nanoparticles Encapsulated with LL37 and Serpin A1 Promotes Wound Healing and Synergistically Enhances Antibacterial Activity.

A novel solid lipid nanoparticle formulation co-delivering LL37 and Serpin A1 at synergistic ratios significantly accelerated wound closure in fibroblast and keratinocyte cells and enhanced antibacterial activity against Staphylococcus aureus and Escherichia coli compared to individual treatments.

The study developed solid lipid nanoparticles encapsulating LL37 and Serpin A1 at specific ratios. In vitro experiments assessed wound closure in BJ fibroblast and keratinocyte cells and antibacterial efficacy against S. aureus and E. coli, comparing combined treatment to single agents.

This approach addresses challenges in chronic wound treatment by providing controlled, sustained delivery of therapeutic peptides that both promote healing and combat infection, potentially reducing reliance on toxic antibiotics.

The study was conducted in vitro, so results may not fully translate to clinical wound healing in humans; the study type and evidence strength were not specified.